301 related articles for article (PubMed ID: 11258897)
21. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
[TBL] [Abstract][Full Text] [Related]
22. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
23. The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity.
Wilmen A; Göke B; Göke R
FEBS Lett; 1996 Nov; 398(1):43-7. PubMed ID: 8946950
[TBL] [Abstract][Full Text] [Related]
24. Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.
Green BD; Irwin N; Gault VA; Bailey CJ; O'Harte FP; Flatt PR
J Endocrinol; 2005 May; 185(2):307-17. PubMed ID: 15845923
[TBL] [Abstract][Full Text] [Related]
25. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes.
Hjorth SA; Adelhorst K; Pedersen BB; Kirk O; Schwartz TW
J Biol Chem; 1994 Dec; 269(48):30121-4. PubMed ID: 7527026
[TBL] [Abstract][Full Text] [Related]
26. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566
[TBL] [Abstract][Full Text] [Related]
27. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro.
Gallwitz B; Ropeter T; Morys-Wortmann C; Mentlein R; Siegel EG; Schmidt WE
Regul Pept; 2000 Jan; 86(1-3):103-11. PubMed ID: 10672909
[TBL] [Abstract][Full Text] [Related]
28. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action.
Hareter A; Hoffmann E; Bode HP; Göke B; Göke R
Endocr J; 1997 Oct; 44(5):701-5. PubMed ID: 9466326
[TBL] [Abstract][Full Text] [Related]
29. A synthetic glucagon-like peptide-1 analog with improved plasma stability.
Ritzel U; Leonhardt U; Ottleben M; Rühmann A; Eckart K; Spiess J; Ramadori G
J Endocrinol; 1998 Oct; 159(1):93-102. PubMed ID: 9795346
[TBL] [Abstract][Full Text] [Related]
30. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
[TBL] [Abstract][Full Text] [Related]
31. Glucagon-like peptides.
Drucker DJ
Diabetes; 1998 Feb; 47(2):159-69. PubMed ID: 9519708
[TBL] [Abstract][Full Text] [Related]
32. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
López de Maturana R; Treece-Birch J; Abidi F; Findlay JB; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):15-22. PubMed ID: 14965274
[TBL] [Abstract][Full Text] [Related]
33. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
[TBL] [Abstract][Full Text] [Related]
34. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Miranda LP; Winters KA; Gegg CV; Patel A; Aral J; Long J; Zhang J; Diamond S; Guido M; Stanislaus S; Ma M; Li H; Rose MJ; Poppe L; Véniant MM
J Med Chem; 2008 May; 51(9):2758-65. PubMed ID: 18412318
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
37. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
38. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1.
Rocca AS; LaGreca J; Kalitsky J; Brubaker PL
Endocrinology; 2001 Mar; 142(3):1148-55. PubMed ID: 11181530
[TBL] [Abstract][Full Text] [Related]
39. Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents.
Han J; Huang Y; Chen X; Zhou F; Fei Y; Fu J
Eur J Med Chem; 2018 Sep; 157():177-187. PubMed ID: 30096651
[TBL] [Abstract][Full Text] [Related]
40. Structure-activity studies of glucagon-like peptide-1.
Adelhorst K; Hedegaard BB; Knudsen LB; Kirk O
J Biol Chem; 1994 Mar; 269(9):6275-8. PubMed ID: 8119974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
